LPCN_1144



NAME OF DRUG : LPCN_1144

ALSO KNOWN AS : LPCN_1144

LABORATORY : LIPOCINE

STATUS AND ADVANCEMENT

Type of drug : novel oral prodrug of testosterone containing testosterone undecanoate

Clinical trials advancement : Analysing Results Phase 1

Estimated time to market : 127 months.

LABORATORY ABSTRACT ON THE DRUG

LPCN 1144, an oral prodrug of bioidentical testosterone, is being developed as a treatment of non-alcoholic steatohepatitis ("NASH") and is currently being studied in a proof-of-concept clinical study

RECENT NEWS ON LPCN_1144

2019-01-17 : Lipocine's NASH Therapy Candidate Achieves Meaningful Liver Fat Reduction Based on Interim Results

SOME PUBLICATIONS RELATED WITH LPCN_1144

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH LPCN_1144


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE